Literature DB >> 23358976

Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.

Floyd Christopher Holsinger1, Sarina Anne Piha-Paul, Filip Janku, David S Hong, Johnique T Atkins, Apostolia M Tsimberidou, Razelle Kurzrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23358976      PMCID： PMC5950501          DOI： 10.1200/JCO.2012.43.2716

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.

Authors:  X Wu; K Senechal; M S Neshat; Y E Whang; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.

Authors:  Sarina A Piha-Paul; Philip R Cohen; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

4.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Authors:  Filip Janku; Apostolia M Tsimberidou; Ignacio Garrido-Laguna; Xuemei Wang; Rajyalakshmi Luthra; David S Hong; Aung Naing; Gerald S Falchook; John W Moroney; Sarina A Piha-Paul; Jennifer J Wheler; Stacy L Moulder; Siqing Fu; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

6.  Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

Authors:  Donatella Del Bufalo; Ludovica Ciuffreda; Daniela Trisciuoglio; Marianna Desideri; Francesco Cognetti; Gabriella Zupi; Michele Milella
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

Review 7.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 8.  Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.

Authors:  Corey J Langer
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

9.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

10.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245
View more
  13 in total

1.  Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

Authors:  S Moulder; T Helgason; F Janku; J Wheler; J Moroney; D Booser; C Albarracin; P K Morrow; J Atkins; K Koenig; M Gilcrease; R Kurzrock
Journal:  Ann Oncol       Date:  2015-04-15       Impact factor: 32.976

2.  PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.

Authors:  Nnamdi Eze; Ju-Whei Lee; Dong-Hua Yang; Fang Zhu; Veronique Neumeister; Teresa Sandoval-Schaefer; Ranee Mehra; John A Ridge; Arlene Forastiere; Christine H Chung; Barbara Burtness
Journal:  Oral Oncol       Date:  2019-03-04       Impact factor: 5.337

3.  Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.

Authors:  Jordi Rodon; Jean-Charles Soria; Raanan Berger; Wilson H Miller; Eitan Rubin; Aleksandra Kugel; Apostolia Tsimberidou; Pierre Saintigny; Aliza Ackerstein; Irene Braña; Yohann Loriot; Mohammad Afshar; Vincent Miller; Fanny Wunder; Catherine Bresson; Jean-François Martini; Jacques Raynaud; John Mendelsohn; Gerald Batist; Amir Onn; Josep Tabernero; Richard L Schilsky; Vladimir Lazar; J Jack Lee; Razelle Kurzrock
Journal:  Nat Med       Date:  2019-04-22       Impact factor: 53.440

4.  Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.

Authors:  Aaron M Goodman; Shumei Kato; Ranajoy Chattopadhyay; Ryosuke Okamura; Ila M Saunders; Meagan Montesion; Garrett M Frampton; Vincent A Miller; Gregory A Daniels; Razelle Kurzrock
Journal:  Cancer Immunol Res       Date:  2019-04-19       Impact factor: 11.151

5.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

6.  Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.

Authors:  Ramiro Iglesias-Bartolome; Daniel Martin; J Silvio Gutkind
Journal:  Cancer Discov       Date:  2013-07       Impact factor: 39.397

7.  A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Authors:  L A Dunn; M G Fury; H Xiao; S S Baxi; E J Sherman; S Korte; C Pfister; S Haque; N Katabi; A L Ho; D G Pfister
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

8.  Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.

Authors:  Maria Schwaederle; Sheryl K Elkin; Brett N Tomson; Jennifer Levin Carter; Razelle Kurzrock
Journal:  Cell Cycle       Date:  2015-06-01       Impact factor: 4.534

9.  Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.

Authors:  Maria Schwaederle; Gregory A Daniels; David E Piccioni; Santosh Kesari; Paul T Fanta; Richard B Schwab; Kelly A Shimabukuro; Barbara A Parker; Razelle Kurzrock
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

10.  TRAIL combinations: The new 'trail' for cancer therapy (Review).

Authors:  Alaa Refaat; Ahmed Abd-Rabou; Asmaa Reda
Journal:  Oncol Lett       Date:  2014-02-27       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.